Results 41 to 50 of about 79,837 (298)

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

ROS-responsive transmembrane peptide-antibody conjugate eyedrops for the non-invasive treatment of choroidoretinopathy

Materials Today Bio
Choroidoretinopathy is a major public health concern that causes significant vision impairment. Although therapeutic antibodies have demonstrated potential in treating these conditions, intravitreal injections remain invasive, associated with adverse ...
Lihang Qu, Tu Lu, Jun Tan, Xinzhao Chen, Tian Tian, Shixiang Liu, Yajun Gong, Zhihao Jiang, Zhonggui He, Peng Sun, Jin Sun, Xiaoli Ma, Ruidong Gu   +12 more
doaj   +1 more source

Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations

Biomolecules, 2020
The ability of monoclonal antibodies to specifically bind a target antigen and neutralize or stimulate its activity is the basis for the rapid growth and development of the therapeutic antibody field.
Hyunbo Shim
doaj   +1 more source

Extracellular vesicles as modifiers of antibody‐drug conjugate efficacy

Journal of Extracellular Vesicles, 2021
Antibody‐drug conjugates (ADCs) are a new class of anti‐cancer drugs that consist of a monoclonal antibody, a highly potent small‐molecule cytotoxic drug, and a chemical linker between the two. ADCs can selectively deliver cytotoxic drugs to cancer cells
Mark Barok, Maija Puhka, Narjes Yazdi, Heikki Joensuu   +3 more
doaj   +1 more source

Progresses in research and development of antibody-drug conjugate

生物医学转化, 2021
Through referring to the literature and related databases, the research process of antibodyconjugated drugs was reviewed, and the key elements of ADC were summarized.
Wu Gang, Fu Zhihao, Xu Gangling, Wang Wenbo, Yu Chuanfei, Wang Lan, Wang Junzhi   +6 more
doaj   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Understanding the Toxicity Profile of Approved ADCs

Pharmaceutics
Background: Antibody–drug conjugates (ADCs) represent a novel therapeutic class that combines an antibody against a tumor-associated antigen (TAA), a payload, and a linker that binds these two components. Serious adverse events (SAEs), particularly those
Pablo Ballestín, Alfonso López de Sá, Cristina Díaz-Tejeiro, Lucía Paniagua-Herranz, Adrián Sanvicente, Igor López-Cade, Pedro Pérez-Segura, Carlos Alonso-Moreno, Cristina Nieto-Jiménez, Alberto Ocaña   +9 more
doaj   +1 more source

Characterizing and understanding the formation of cysteine conjugates and other by-products in a random, lysine-linked antibody drug conjugate

mAbs, 2021
This study describes the characterization of conjugation sites for a random, lysine conjugated 2-iminothiolane (2-IT) based antibody-drug-conjugate synthesized from an IgG1 antibody and a duocarmycin analog-based payload-linker. Of the 80 putative lysine
Difei Qiu, Yande Huang, Naresh Chennamsetty, Scott A. Miller, Michael Hay   +4 more
doaj   +1 more source

689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study [PDF]

, 2023
Omkar Marathe, Ying Cheng, Alexander I. Spira, Erika Hamilton, Maria M. Rubinstein, X. Dong, Li Li, Dongqing Lv, Jingyun Shi, Nashat Gabrail, H. Amin, C. Wu, Zhe Zhu, Yue Qiu, Vivian W. Gu, Xueting Qiu, Rui Shi, Li Liu, Ping Miao, Naoto T. Ueno   +19 more
openalex   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source